Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702236 | 0.92 | P2RY12 (0.34) | BDKRB2F10PDK1PDK2PDK3 | |
| SCHEMBL4700441 | 0.89 | BDKRB2 (0.38) | BDKRB2TAS1R3TAS1R1OPRM1OPRK1 | |
| SCHEMBL4698315 | 0.88 | ROCK2 (0.34) | BDKRB2F10PDK1PDK2PDK3 | |
| SCHEMBL4698540 | 0.85 | OPRM1 (0.35) | BDKRB2F10PDK1PDK2PDK3 | |
| SCHEMBL4703609 | 0.82 | AVPR2 (0.39) | BDKRB2PDK1PDK2PDK3PDK4 | |
| SCHEMBL4700242 | 0.82 | PDK1 (0.40) | BDKRB2PDK1PDK2PDK3PDK4 | |
| SCHEMBL4698850 | 0.81 | BDKRB2 (0.35) | BDKRB2TAS1R3TAS1R1OPRM1OPRK1 | |
| SCHEMBL4756002 | 0.80 | ALDH1A1 (0.39) | BDKRB2TAS1R3TAS1R1OPRM1OPRK1 | |
| SCHEMBL4698590 | 0.78 | BDKRB2 (0.40) | BDKRB2ALDH1A1L3MBTL1ROCK2KMT2A | |
| SCHEMBL4701325 | 0.77 | RAB9A (0.39) | BDKRB2TAS1R3TAS1R1ALDH1A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | claimed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| EP-1458684-B1 | THERAPEUTIC HETEROCYCLES AS BRADYKININ B2 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | BDKRB2 73/4885F10 471/4885PDK1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.